pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The May 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:
- Three negotiations were completed, while three more were closed for a total of 215 completed/closed negotiations;
- Three new drug products have initiated pCPA negotiations, for a total of 42 active negotiations;
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.
Negotiations Completed/Closed
- Three negotiations were completed since the last update, for a total of 190 completed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Negotiation Initiation | Duration * |
|---|---|---|---|---|---|
| Elelyso | Taliglucerase alfa | Pfizer Canada Inc | Gaucher Disease | November, 2017 | 181 days |
| Lynparza | olaparib | Astra Zeneca Canada Inc | Ovarian Cancer | October, 2017 | 212 days |
| VPRIV | Velaglucerase alfa | Shire Human genetic therapies | Gaucher Disease | November, 2017 | 181 days |
*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation
Signals Decoded:
It appears that pCPA has completed the class negotiation for Gaucher Disease, having reached agreements for Elelyso and VPRIV. Elelyso was successfully negotiated despite receiving a “Do Not List” recommendation from CDEC in 2015.
- Three negotiations were closed since the last update, for a total of 25 closed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Negotiation Initiation | Duration * |
|---|---|---|---|---|---|
| Cerdelga | eliglustat | Sanofi Genzyme | Gaucher Disease | November, 2017 | 181 days |
| Cerezyme | Imiglucerase | Sanofi Genzyme | Gaucher Disease | November, 2017 | 181 days |
| Rosiver | Ivermectin | Galderma Canada Inc. | Rosacea | February, 2018 | 90 days |
*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation
Signals Decoded:
By closing negotiations without an agreement, the pCPA has signaled that the future reimbursement status of Cerezyme may be changing, while Cerdelga – the most recent treatment for Gaucher Disease to come to market and the likely “trigger” for this class negotiation – will not be reimbursed at this time. In addition, Rosiver becomes the first file to re- enter negotiations, only to be closed without an agreement for a second time.
Negotiation Initiation
- Three new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation/Notification to Implement Date | Time to Initiation* |
|---|---|---|---|---|---|
| Dysport Therapeutic | abobotulinumtoxinA | IPSEN Biopharmaceuticals Canada, Inc | Upper limb spasticity | October 24, 2017 | 203 |
| Dysport Therapeutic | abobotulinumtoxinA | IPSEN Biopharmaceuticals Canada, Inc | Cervical dystonia | July 26, 2017 | 293 |
| Enstilar | betamethasone& calcipotriol | Leo Pharma Inc. | Psoriasis | N/A | N/A |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
No pCPA Negotiation
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined collective or provincial/territorial-level negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Final Recommendation/ Notification to Implement</th | Time to Decision* |
|---|---|---|---|---|---|
| Vectibix | Panitumumab | Amgen Canada Inc. | Left Sided Metastatic Colorectal Cancer | April 16, 2018 | 29 |
*Approximation: Decision date assumed to be mid-month
Files Under pCPA Consideration
In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.
- Five new drug products received a CDEC or pERC recommendation or notification to implement in May 2018, for a total of approximately 30 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Final Recommendation/Notification to Implement |
|---|---|---|---|---|
| Kisqali | ribociclib | Novartis Pharmaceuticals Canada Inc. | Advanced or Metastatic Breast Cancer | Conditional Reimbursement |
| Lapelga | Pegfilgrastim | Apobiologix | Febrile neutropenia | N/A
Biosimilar |
| Lartruvo | olaratumab | Eli Lilly Canada Inc, | Advanced soft tissue sarcoma (STS) | Conditional Reimbursement |
| Opdivo | Nivolumab | Bristol-Myers Squibb | classical Hodgkin Lymphoma after failure of ASCT | Conditional Reimbursement |
| Stivarga | Regorafenib | Bayer Inc | Unresectable Hepatocellular Carcinoma (HCC) | Conditional Reimbursement |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
